Small cell carcinoma of the bladder

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:284400C67.1C67.2C67.3
Who is this for?
Show terms as
3FDA treatments9Active trials28Specialists8Treatment centers1Financial resources

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Small cell carcinoma of the bladder is a very rare and aggressive type of bladder cancer. Unlike the more common form of bladder cancer (called urothelial or transitional cell carcinoma), small cell carcinoma is made up of small, round cancer cells that grow and spread quickly. This cancer type is similar to small cell lung cancer in how it looks under a microscope and how it behaves, but it starts in the bladder instead of the lungs. Symptoms often include blood in the urine (which may be visible or only found on a urine test), frequent or painful urination, pelvic pain, and sometimes difficulty urinating. Because this cancer tends to grow fast, it may already have spread to other parts of the body by the time it is found. Patients may also experience weight loss, fatigue, and bone pain if the cancer has spread. Treatment usually involves a combination of chemotherapy and surgery or radiation therapy. Chemotherapy regimens similar to those used for small cell lung cancer — typically cisplatin and etoposide — are commonly used. Surgery to remove the bladder (radical cystectomy) may also be recommended. Because this cancer is so rare, treatment plans are often based on experience with small cell lung cancer and on case reports rather than large clinical trials. Early and aggressive treatment gives the best chance of controlling the disease.

Also known as:

Key symptoms:

Blood in the urine (hematuria)Frequent urinationPainful urinationDifficulty urinatingPelvic or lower abdominal painUnexplained weight lossFatigue and weaknessBone pain if cancer has spreadLoss of appetiteFeeling of incomplete bladder emptyingBack pain or flank painSwelling in the legs if lymph nodes are involved

Clinical phenotype terms (6)— hover any for plain English
Bladder neoplasmHP:0009725
Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Late onset

Begins later in life, typically after age 50

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Nov 2025A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Rondo Therapeutics — PHASE1

TrialENROLLING BY INVITATION
Aug 2024Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...

National Cancer Institute (NCI) — PHASE2

TrialRECRUITING
Jun 2024Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

National Cancer Institute (NCI) — PHASE2

TrialRECRUITING
Mar 2024A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BeiGene — PHASE1

TrialRECRUITING
Jun 2022Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — PHASE2

TrialRECRUITING
Mar 2022Quantifying Systemic Immunosuppression to Personalize Cancer Therapy

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

TrialRECRUITING
Nov 2021MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

Invitae Corporation

TrialACTIVE NOT RECRUITING
Apr 2021Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

IDEAYA Biosciences — PHASE1

TrialRECRUITING
Nov 2020Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

AstraZeneca — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING
Jul 2020Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

BicycleTx Limited — PHASE1, PHASE2

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

3 available

IMFINZI

durvalumab· AstraZeneca Pharmaceuticals LP
in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with mu

in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC)

TEPADINA

THIOTEPA· Amneal Pharmaceuticals LLC■ Boxed Warning

For treatment of superficial papillary carcinoma of the urinary bladder

Valstar

Valrubicin· Anthra Pharmaceuticals, Inc.Orphan Drug

For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.

Clinical Trials

9 recruitingView all trials with filters →
Phase 24 trials
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Phase 2
Actively Recruiting
PI: Andrea B Apolo, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 18120 yrs
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Phase 2
Actively Recruiting
PI: Jean Hoffman-Censits, MD (Johns Hopkins University) · Sites: Washington D.C., District of Columbia; Baltimore, Maryland · Age: 1899 yrs
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium
Phase 2
Active
PI: Seungtaek Choi, MD (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 1899 yrs
Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)
Phase 2
Actively Recruiting
PI: Andrea B Apolo, M.D. (National Cancer Institute (NCI)) · Sites: Bethesda, Maryland · Age: 18120 yrs
Phase 12 trials
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Phase 1
Enrolling by Invitation
PI: Thomas Manley, MD (Rondo Therapeutics) · Sites: Grand Rapids, Michigan; Huntersville, North Carolina +5 more · Age: 1899 yrs
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1
Actively Recruiting
PI: Study Director (BeiGene) · Sites: Newport Beach, California; Lake Mary, Florida +22 more · Age: 1899 yrs
Other2 trials
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
Active
PI: Ed Esplin, MD, PhD (Invitae Corporation) · Sites: Columbus, Indiana; Jacksonville, North Carolina · Age: 1899 yrs
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
Actively Recruiting
PI: Licia Rivoltini (Fondazione IRCCS Istituto Nazionale Tumori - Milan) · Sites: Milan · Age: 1890 yrs

Specialists

Showing 25 of 28View all specialists →
LR
Licia Rivoltini
Specialist
PI on 1 active trial2 Small cell carcinoma of the bladder publications
AA
Andrea B Apolo
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 4 active trials
DM
David Hong, MD
Specialist
PI on 5 active trials
WM
Willis Navarro, MD
TUCSON, AZ
Specialist
PI on 4 active trials
NM
Nina Merchant
Specialist
PI on 1 active trial
NM
Nagla Karim, MD
Specialist
PI on 1 active trial
SM
Samuel Funt, MD
NEW YORK, NY
Specialist
PI on 3 active trials
JM
Jonathan W Riess, MD, MSc
SACRAMENTO, CA
Specialist
PI on 1 active trial
AM
Anish Thomas, M.D.
Specialist
PI on 7 active trials
TY
Timothy Yap
HOUSTON, TX
Specialist
PI on 1 active trial13 Small cell carcinoma of the bladder publications
AM
Atif Khan, MD
Specialist
PI on 1 active trial
JM
Joao da Silva, MD
TAUNTON, MA
Specialist
PI on 1 active trial
DY
Don Yee
SILVER SPRING, MD
Specialist
PI on 1 active trial
JH
Jean Hoffman-Censits
BALTIMORE, MD
Specialist
PI on 1 active trial
AA
Andrew J Armstrong
Specialist
PI on 1 active trial
IP
Ira Pastan
Specialist
PI on 1 active trial
HP
Hardev Pandha
Specialist
PI on 1 active trial
EE
Ed Esplin
STANFORD, CA
Specialist
PI on 1 active trial
DB
Deborah Bradley
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Financial Resources

1 resources
IMFINZI(durvalumab)AstraZeneca Pharmaceuticals LP

Travel Grants

No travel grants are currently matched to Small cell carcinoma of the bladder.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Small cell carcinoma of the bladderForum →

No community posts yet. Be the first to share your experience with Small cell carcinoma of the bladder.

Start the conversation →

Latest news about Small cell carcinoma of the bladder

2 articles
Clinical trialCLINICALTRIALSApr 24, 2026
Trial Now Recruiting: A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (NCT06010329)
Researchers are testing a new cancer drug called sutetinib maleate in people with advanced lung cancer that has specific uncommon genetic mutations. This is a P
Clinical trialCLINICALTRIALSApr 24, 2026
Trial Now Recruiting: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations (NCT06706076)
Researchers are testing a new drug called BH-30643 for advanced lung cancer patients whose tumors have specific genetic mutations (EGFR or HER2). The study will
See all news about Small cell carcinoma of the bladder

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my cancer, and has it spread beyond the bladder?,What treatment plan do you recommend, and why?,Am I a candidate for surgery, and what would life be like after bladder removal?,Are there any clinical trials available for small cell carcinoma of the bladder?,What side effects should I expect from chemotherapy, and how can they be managed?,Should my tumor be tested for specific mutations that might guide treatment?,What support services are available to help me and my family cope with this diagnosis?

Common questions about Small cell carcinoma of the bladder

What is Small cell carcinoma of the bladder?

Small cell carcinoma of the bladder is a very rare and aggressive type of bladder cancer. Unlike the more common form of bladder cancer (called urothelial or transitional cell carcinoma), small cell carcinoma is made up of small, round cancer cells that grow and spread quickly. This cancer type is similar to small cell lung cancer in how it looks under a microscope and how it behaves, but it starts in the bladder instead of the lungs. Symptoms often include blood in the urine (which may be visible or only found on a urine test), frequent or painful urination, pelvic pain, and sometimes diffic

How is Small cell carcinoma of the bladder inherited?

Small cell carcinoma of the bladder follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Small cell carcinoma of the bladder typically begin?

Typical onset of Small cell carcinoma of the bladder is late onset. Age of onset can vary across affected individuals.

Are there clinical trials for Small cell carcinoma of the bladder?

Yes — 9 recruiting clinical trials are currently listed for Small cell carcinoma of the bladder on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Small cell carcinoma of the bladder?

25 specialists and care centers treating Small cell carcinoma of the bladder are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.

What treatment and support options exist for Small cell carcinoma of the bladder?

1 patient support program are currently tracked on UniteRare for Small cell carcinoma of the bladder. See the treatments and support programs sections for copay assistance, eligibility, and contact details.